BACKGROUND AND OBJECTIVES: From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg(1.5)/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients younger than 3 years. Compared with traditional dosing, this model-derived dosing regimen yields significantly reduced doses in neonates aged <10 days. METHODS: Concentration predictions of the population model were prospectively evaluated in postoperative term neonates and infants up to the age of 1 year who received morphine doses according to the model-derived algorithm. The efficacy of this dosing algorithm was evaluated using morphine rescue medication and actual average infusion rates. RESULTS:Morphine and metabolite concentrations were accurately predicted by the paediatric pharmacokinetic morphine model. With regard to efficacy, 5 out of 18 neonates (27.8 %) with a PNA of <10 days needed rescue medication versus 18 of the 20 older patients (90 %) (p = 0.06). The median (interquartile range [IQR]) total morphine rescue dose was 0 (0-20) μg/kg in younger patients versus 193 (19-362) μg/kg in older patients (p = 0.003). The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001). CONCLUSION:Morphine paediatric dosing algorithms corrected for pharmacokinetic differences alone yield effective doses that prevent over-dosing for neonates with a PNA <10 days. The fact that many neonates and infants with a PNA ≥10 days still required rescue medication warrants pharmacodynamic studies to further optimize the dosing algorithm for these patients.
RCT Entities:
BACKGROUND AND OBJECTIVES: From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg(1.5)/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients younger than 3 years. Compared with traditional dosing, this model-derived dosing regimen yields significantly reduced doses in neonates aged <10 days. METHODS: Concentration predictions of the population model were prospectively evaluated in postoperative term neonates and infants up to the age of 1 year who received morphine doses according to the model-derived algorithm. The efficacy of this dosing algorithm was evaluated using morphine rescue medication and actual average infusion rates. RESULTS:Morphine and metabolite concentrations were accurately predicted by the paediatric pharmacokinetic morphine model. With regard to efficacy, 5 out of 18 neonates (27.8 %) with a PNA of <10 days needed rescue medication versus 18 of the 20 older patients (90 %) (p = 0.06). The median (interquartile range [IQR]) total morphine rescue dose was 0 (0-20) μg/kg in younger patients versus 193 (19-362) μg/kg in older patients (p = 0.003). The median (IQR) actual average morphine infusion rate was 4.4 (4.0-4.8) μg/kg/h in younger patients versus 14.4 (11.3-23.4) μg/kg/h in older patients (p < 0.001). CONCLUSION:Morphine paediatric dosing algorithms corrected for pharmacokinetic differences alone yield effective doses that prevent over-dosing for neonates with a PNA <10 days. The fact that many neonates and infants with a PNA ≥10 days still required rescue medication warrants pharmacodynamic studies to further optimize the dosing algorithm for these patients.
Authors: Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe Journal: Eur J Clin Pharmacol Date: 2010-03-26 Impact factor: 2.953
Authors: Ilse Ceelie; Saskia N de Wildt; Monique van Dijk; Margreeth M J van den Berg; Gerbrich E van den Bosch; Hugo J Duivenvoorden; Tom G de Leeuw; Ron Mathôt; Catherijne A J Knibbe; Dick Tibboel Journal: JAMA Date: 2013-01-09 Impact factor: 56.272
Authors: Elke H J Krekels; Joost DeJongh; Richard A van Lingen; Caroline D van der Marel; Imti Choonara; Anne M Lynn; Meindert Danhof; Dick Tibboel; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2011-01 Impact factor: 6.447
Authors: Alexander A Vinks; Nieko C Punt; Frank Menke; Eric Kirkendall; Dawn Butler; Thomas J Duggan; DonnaMaria E Cortezzo; Sam Kiger; Tom Dietrich; Paul Spencer; Rob Keefer; Kenneth D R Setchell; Junfang Zhao; Joshua C Euteneuer; Tomoyuki Mizuno; Kevin R Dufendach Journal: Clin Pharmacol Ther Date: 2019-12-11 Impact factor: 6.875
Authors: Niina Kleiber; Krista Tromp; Miriam G Mooij; Suzanne van de Vathorst; Dick Tibboel; Saskia N de Wildt Journal: Paediatr Drugs Date: 2015-02 Impact factor: 3.022
Authors: Esther J H Janssen; Pyry A J Välitalo; Karel Allegaert; Roosmarijn F W de Cock; Sinno H P Simons; Catherine M T Sherwin; Johan W Mouton; Johannes N van den Anker; Catherijne A J Knibbe Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Adam Frymoyer; Sonia L Bonifacio; David R Drover; Felice Su; Courtney J Wustoff; Krisa P Van Meurs Journal: J Clin Pharmacol Date: 2016-06-26 Impact factor: 3.126
Authors: Justine Badée; Stephen Fowler; Saskia N de Wildt; Abby C Collier; Stephan Schmidt; Neil Parrott Journal: Clin Pharmacokinet Date: 2019-02 Impact factor: 6.447
Authors: Joshua C Euteneuer; Suyog Kamatkar; Tsuyoshi Fukuda; Alexander A Vinks; Henry T Akinbi Journal: J Clin Pharmacol Date: 2018-09-11 Impact factor: 3.126